ReviewJournal of nephrology2019
Kidney transplantation in ANCA-associated vasculitis.
Review in Journal of nephrology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 20 citations in OpenAlex.
- 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.Arthritis care & research · 2021Guideline
- 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.Arthritis & rheumatology (Hoboken, N.J.) · 2021Guideline
- Longitudinal Trajectories of Kidney Function in Patients with Severe ANCA-Associated Vasculitis.Clinical journal of the American Society of Nephrology : CJASN · 2026Article
- Outcomes After Kidney Transplantation in Antineutrophil Cytoplasmic Autoantibody-Associated Renal Vasculitis.Kidney international reports · 2025Article
- The Recurrence of Systemic Diseases in Kidney Transplantation.Journal of clinical medicine · 2025Review
- Kidney transplantation in patients with ANCA-associated vasculitis is associated with a high incidence of post-transplant cancer.Journal of nephrology · 2024Article
- Longitudinal Patterns of Renal Function in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.Arthritis care & research · 2023Article
- Evaluation of a renal risk score for Japanese patients with ANCA-associated glomerulonephritis in a multi-center cohort study.Frontiers in immunology · 2023Article
- Very Early Severe Posttransplant Recurrent Antineutrophil Cytoplasmic Antibody-Associated Glomerulonephritis after Kidney Transplantation: Two Case Reports.Case reports in nephrology · 2022Article
- Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis in Kidney Transplantation.Medicina (Kaunas, Lithuania) · 2021Review
- ANCA-Associated Glomerulonephritis: Diagnosis and Therapy Proceedings of the Henry Shavelle Lectureship.Glomerular diseasesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The kidney is commonly affected in patients with ANCA-associated vasculitis (AAV), causing end-stage renal disease (ESRD) in 20-40% of cases. Kidney transplantation is the treatment of choice for eligible patients with ESRD due to AAV. This review provides a summary of patient and graft outcome after kidney transplantation in AAV patients, the risk of relapse and the optimal time of transplantation. We also address the rare event of de novo ANCA-associated vasculitis after kidney transplantation and the treatment options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.